Literature DB >> 36063245

Reactions of Ru(III)-drugs KP1019 and KP418 with guanine, 2'-deoxyguanosine and guanosine: a DFT study.

Pramod Kumar Shah1, Nihar R Jena2, Pradeep Kumar Shukla3.   

Abstract

Ruthenium (Ru)-based anticancer drugs are considered to be novel alternatives of platinum-based drugs. They exhibit potent cytotoxicity against the cancer cells and hence are useful for the treatment of cancer. Herein, the density functional theory calculations in the gas phase and aqueous media are carried out to study the reactions of two Ru(III)-based drugs such as KP1019 and KP418 with the N7 site of guanine (G), 2'-deoxyguanosine (dGua), and guanosine (Gua) to understand their reactivity against the DNA and RNA. All the reactions are found to be exothermic. The activation free energies and rate constants of these reactions indicate that KP1019 and KP418 would react with the dGua more readily than Gua. Hence, the binding of these drugs with the DNA would be more preferred as compared to RNA. It is further found that among these drugs, KP1019 would be more reactive than KP418 in agreement with the experimental observation. Thus, this study is expected to aid in the future development of potent anticancer drugs.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  2′-Deoxyguanosine; DFT; Guanine; Guanosine; KP1019; KP418; Ruthenium anticancer drugs

Mesh:

Substances:

Year:  2022        PMID: 36063245     DOI: 10.1007/s00894-022-05304-7

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   2.172


  26 in total

Review 1.  Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.

Authors:  Markus Galanski; Michael A Jakupec; Bernhard K Keppler
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 2.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

Review 3.  Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

Authors:  A Bergamo; C Gaiddon; J H M Schellens; J H Beijnen; G Sava
Journal:  J Inorg Biochem       Date:  2011-09-29       Impact factor: 4.155

4.  Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

Authors:  Alberta Bergamo; Gianni Sava
Journal:  Dalton Trans       Date:  2011-06-01       Impact factor: 4.390

Review 5.  Cisplatin: The first metal based anticancer drug.

Authors:  Sumit Ghosh
Journal:  Bioorg Chem       Date:  2019-04-11       Impact factor: 5.275

Review 6.  Ruthenium complexes as anticancer agents.

Authors:  Irena Kostova
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

7.  The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.

Authors:  Marina Bacac; Anna C G Hotze; Karlijn van der Schilden; Jaap G Haasnoot; Sabrina Pacor; Enzo Alessio; Gianni Sava; Jan Reedijk
Journal:  J Inorg Biochem       Date:  2004-02       Impact factor: 4.155

Review 8.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

Review 9.  Metal-based drugs that break the rules.

Authors:  Claire S Allardyce; Paul J Dyson
Journal:  Dalton Trans       Date:  2016-01-28       Impact factor: 4.390

10.  Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential.

Authors:  Michael A Jakupec; Erwin Reisner; Anna Eichinger; Martina Pongratz; Vladimir B Arion; Mathea Sophia Galanski; Christian G Hartinger; Bernhard K Keppler
Journal:  J Med Chem       Date:  2005-04-21       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.